Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 14:9:2020-7-2.
doi: 10.7573/dic.2020-7-2. eCollection 2020.

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Diego Conde-Royo  1 , Luis Miguel Juárez-Salcedo  2 , Samir Dalia  3
Affiliations
Review

Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia

Diego Conde-Royo et al. Drugs Context. .

Abstract

Therapeutic options for relapsed/refractory B-cell acute lymphoblastic leukemia have evolved in the past few years. The FDA has approved three novel therapies for this disease: inotuzumab ozogamicin (an anti-CD22 antibody-drug conjugate), blinatumomab (a bispecific T-cell engager), and chimeric antigen receptor T-cell therapy. Although these novel immunotherapies have revolutionized the therapeutic landscape, it is important to understand the crucial aspects of administration, especially toxicity. In this article, we review the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.

Keywords: acute lymphoblastic leukemia; blinatumomab; immunotherapy; inotuzumab; side effects.

PubMed Disclaimer

Conflict of interest statement

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/09/dic.2020-7-2-COI.pdf

References

    1. Acute Lymphocytic Leukemia – Cancer Stat Facts. SEER; [Accessed June 11, 2020]. https://seer.cancer.gov/statfacts/html/alyl.html.
    1. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724–3734. doi: 10.1182/blood-2010-05-282632. - DOI - PubMed
    1. DeAngelo DJ, Jabbour E, Advani A. Recent advances in managing acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2020;40:330–342. doi: 10.1200/EDBK_280175. - DOI - PubMed
    1. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767. doi: 10.1182/blood-2005-04-1623. - DOI - PubMed
    1. Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645–1666. doi: 10.1016/j.mayocp.2016.09.010. - DOI - PubMed